Bleakley Financial Group LLC Has $610,000 Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Bleakley Financial Group LLC boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,590 shares of the biopharmaceutical company’s stock after acquiring an additional 375 shares during the quarter. Bleakley Financial Group LLC’s holdings in Alnylam Pharmaceuticals were worth $610,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of ALNY. Jennison Associates LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $61,160,000. Los Angeles Capital Management LLC lifted its position in Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after buying an additional 135,829 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $578,000. Assenagon Asset Management S.A. grew its holdings in shares of Alnylam Pharmaceuticals by 13.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock valued at $4,687,000 after acquiring an additional 2,285 shares in the last quarter. Finally, Toronto Dominion Bank increased its stake in shares of Alnylam Pharmaceuticals by 27.3% in the third quarter. Toronto Dominion Bank now owns 15,466 shares of the biopharmaceutical company’s stock worth $4,254,000 after acquiring an additional 3,315 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $276.19 on Monday. The stock has a market cap of $35.62 billion, a PE ratio of -105.42 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The stock’s 50 day simple moving average is $252.78 and its 200-day simple moving average is $262.47. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $1,309,864.62. Following the transaction, the chief executive officer now owns 78,880 shares of the company’s stock, valued at approximately $19,797,302.40. This represents a 6.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 73,964 shares of company stock valued at $20,622,925 in the last 90 days. 1.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Raymond James lifted their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 9th. Barclays raised their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Finally, TD Cowen raised their price target on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a report on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $298.61.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.